CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...

[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

William Wood, an analyst from B.Riley Financial, reiterated the Buy rating on ClearPoint Neuro (CLPT – Research Report). The associated price target is $10.00. William Wood’s rating is based on ...

SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, ...

Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ...